Economic evaluation uncovers lecanemab cost-effectiveness in early-stage Alzheimer disease, highlighting the impact of diagnostic test accuracy.
Little is known regarding the cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). This study aims to quantify the cost-effectiveness of lecanemab and how it varies based on the accuracy of AD testing and individuals'
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: